Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Chronic Pruritus Therapeutics Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The market size of chronic pruritus therapeutics has seen robust growth in the past few years. The predicted growth of this market is set to increase from $10.17 billion in 2024 to $10.94 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%. This historical growth is mainly due to the increased prevalence of chronic pruritus, a surge in demand for effective treatment options, an escalation in regulatory approvals, augmented product endorsements, and a rise in the frequency of mergers, collaborations, and acquisitions amongst industry participants.

The market for therapeutics for chronic pruritus is anticipated to experience vigorous growth in the coming years. It’s projected to reach a value of $14.49 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.3%. The projected increase within the forecast period could be ascribed to escalating awareness, upsurge in atopic dermatitis, amplified emphasis on personalized medication, rising instances of dermatological diseases, and an expanding patient population. The predominant trends for the forecast period comprise the introduction of innovative drugs, the development of groundbreaking biologics and targeted treatments, technological advancements, the incorporation of sophisticated drug delivery systems, partnerships between pharmaceutical firms and research institutions, and digital healthcare technologies including telemedicine.

What Drivers Are Shaping the Growth of the Chronic Pruritus Therapeutics Market?

The surge in the number of atopic dermatitis cases is predicted to fuel the expansion of the chronic pruritus therapeutics market in the future. Characterized by inflammation, redness, itchiness, dryness, and discomfort, atopic dermatitis (AD) tends to frequently impact individuals who have a familial history of allergies, asthma, or hayfever. The escalating incidence of atopic dermatitis can be traced back to elements such as genetic tendencies, alterations in the environment, lifestyle influences, the hygiene hypothesis, elevated exposure to allergens, and imbalances in the skin’s microbiome. Chronic pruritus therapeutics help relieve the unwavering itching linked with atopic dermatitis by addressing the root inflammatory pathways, minimizing skin inflammation, and elevating patient comfort. For example, the International Eczema Council, a non-profit organization based in the US, revealed in 2022 that approximately 223 million individuals around the world were diagnosed with atopic dermatitis (GBD 2022), 43 million of whom are children between 1-4 years old. This data underscores the significant prevalence of the condition in early youth. Consequently, the escalating prevalence of atopic dermatitis is leading to the expansion of the chronic pruritus therapeutics market.

Request Your Free Chronic Pruritus Therapeutics Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Who Are the Influential Players Reshaping the Chronic Pruritus Therapeutics Market Landscape?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

What New and Evolving Trends Are Having a Lasting Impact on the Chronic Pruritus Therapeutics Market?

Major firms active in the chronic pruritus therapeutics market are currently oriented toward innovation with an emphasis on developing novel solutions such as intravenous (IV) injections to boost therapeutic effectiveness and deliver more immediate relief for patients. This process works by thrusting drugs, including antihistamines or corticosteroids, into the bloodstream to expeditiously relieve itching and minimize inflammation. For instance, in September 2023, the US firm Cara Therapeutics Inc., known for manufacturing therapeutics, announced that its ally firm, Maruishi Pharmaceutical Co. Ltd., based in Japan got the authorization for Korsuva IV injection syringe, a pruritus treatment for hemodialysis patients, from the Japan’s Ministry of Health, Labour and Welfare, a Japanese governmental agency. This green light was given in light of favorable results from Phase 3 clinical trials conducted by Maruishi in partnership with Kissei Pharmaceutical Co., Ltd. The treatment notably improved itching scores against a placebo and was well received by patients. This approval additionally set off a $1.5 million milestone payment to Cara Therapeutics, the creator of Korsuva, as outlined in their agreement with Maruishi.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Key Segments Stand Out in Understanding the Composition of the Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Which Geographic Locations Are Critical to the Growth of the Chronic Pruritus Therapeutics Market?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Chronic Pruritus Therapeutics Market?

Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Pediatric Bladder Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: